Pharmaceutical manufacturing’s digital transformation is constrained not by a lack of data, but by decision velocity: the speed, quality, and auditability of translating operational signals into compliant actions.

Quality professionals in all industries are heavily involved in root-cause analysis (RCA) and corrective and preventive action (CAPA) management. As artificial intelligence (AI) systems emerge to augment these quality functions, the industry faces a fundamental challenge: no comprehensive regulatory framework exists to govern AI application in GxP environments.

As artificial intelligence (AI), digital transformation, and evolving regulatory expectations continue to reshape the pharmaceutical industry, organizations face a critical challenge: how to innovate while maintaining compliance, quality, and patient safety.